[1]
Fry, B.G. From genome to “venome”: Molecular origin and evolution of the snake venom proteome inferred from phylogenetic analysis of toxin sequences and related body proteins. Genome Res., 2005, 15(3), 403-420.
[2]
Koh, C.Y.; Modahl, C.M.; Kulkarni, N.; Kini, R.M. Toxins are an excellent source of therapeutic agents against cardiovascular diseases. Semin. Thromb. Hemost., 2018, 44(7), 691-706.
[3]
Koh, C.Y.; Kini, R.M. Molecular diversity of anticoagulants from haematophagous animals. Thromb. Haemost., 2009, 102(3), 437-453.
[5]
Vink, S.; Jin, A.H.; Poth, K.J.; Head, G.A.; Alewood, P.F. Natriuretic peptide drug leads from snake venom. Toxicon, 2012, 59(4), 434-445.
[6]
Ichiki, T.; Dzhoyashvili, N.; Burnett, J.C., Jr Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. Int. J. Cardiol., 2019, 281, 166-171.
[8]
Campbell, I.D.; Humphries, M.J. Integrin structure, activation, and interactions. Cold Spring Harb. Perspect. Biol., 2011, 3(3), pii: a004994.
[9]
Perchuc, A.M.; Wilmer, M. In Toxins and Hemostasis: From Bench to Bedside; Kini, R.M.; Clemetson, K.J.; Markland, F.S.; McLane, M.A.; Morita, T., Eds.; Springer Netherlands: Dordrecht, 2010, pp. 747-766.
[10]
Lee, C.J.; Ansell, J.E. Direct thrombin inhibitors. Br. J. Clin. Pharmacol., 2011, 72(4), 581-592.
[11]
Erlinge, D.; Omerovic, E.; Frobert, O.; Linder, R.; Danielewicz, M.; Hamid, M.; Swahn, E.; Henareh, L.; Wagner, H.; Hardhammar, P.; Sjogren, I.; Stewart, J.; Grimfjard, P.; Jensen, J.; Aasa, M.; Robertsson, L.; Lindroos, P.; Haupt, J.; Wikstrom, H.; Ulvenstam, A.; Bhiladvala, P.; Lindvall, B.; Lundin, A.; Todt, T.; Ioanes, D.; Ramunddal, T.; Kellerth, T.; Zagozdzon, L.; Gotberg, M.; Andersson, J.; Angeras, O.; Ostlund, O.; Lagerqvist, B.; Held, C.; Wallentin, L.; Schersten, F.; Eriksson, P.; Koul, S.; James, S. Bivalirudin versus Heparin monotherapy in myocardial infarction. N. Engl. J. Med., 2017, 377(12), 1132-1142.
[12]
Stassens, P.; Bergum, P.W.; Gansemans, Y.; Jespers, L.; Laroche, Y.; Huang, S.; Maki, S.; Messens, J.; Lauwereys, M.; Cappello, M.; Hotez, P.J.; Lasters, I.; Vlasuk, G.P. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc. Natl. Acad. Sci. USA, 1996, 93(5), 2149-2154.
[13]
Giugliano, R.P.; Wiviott, S.D.; Stone, P.H.; Simon, D.I.; Schweiger, M.J.; Bouchard, A.; Leesar, M.A.; Goulder, M.A.; Deitcher, S.R.; McCabe, C.H.; Braunwald, E. Investigators, A.-T.-. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J. Am. Coll. Cardiol., 2007, 49(25), 2398-2407.
[14]
Moons, A.H.; Peters, R.J.; Bijsterveld, N.R.; Piek, J.J.; Prins, M.H.; Vlasuk, G.P.; Rote, W.E.; Buller, H.R. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J. Am. Coll. Cardiol., 2003, 41(12), 2147-2153.
[15]
Lee, A.; Agnelli, G.; Buller, H.; Ginsberg, J.; Heit, J.; Rote, W.; Vlasuk, G.; Costantini, L.; Julian, J.; Comp, P.; van Der Meer, J.; Piovella, F.; Raskob, G.; Gent, M. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation, 2001, 104(1), 74-78.
[16]
Levy, D.E.; del Zoppo, G.J.; Demaerschalk, B.M.; Demchuk, A.M.; Diener, H.C.; Howard, G.; Kaste, M.; Pancioli, A.M.; Ringelstein, E.B.; Spatareanu, C.; Wasiewski, W.W. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke, 2009, 40(12), 3796-3803.
[17]
Yamada, D.; Morita, T. CA-1 method, a novel assay for quantification of normal prothrombin using a Ca2+ -dependent prothrombin activator, carinactivase-1. Thromb. Res., 1999, 94(4), 221-226.
[18]
Medcalf, R.L. Desmoteplase: Discovery, insights and opportunities for ischaemic stroke. Br. J. Pharmacol., 2012, 165(1), 75-89.
[19]
Albers, G.W.; von Kummer, R.; Truelsen, T.; Jensen, J.K.; Ravn, G.M.; Gronning, B.A.; Chabriat, H.; Chang, K.C.; Davalos, A.E.; Ford, G.A.; Grotta, J.; Kaste, M.; Schwamm, L.H.; Shuaib, A.; Investigators, D. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol., 2015, 14(6), 575-584.
[20]
Markland, F.S.; Swenson, S. Fibrolase: Trials and tribulations. Toxins (Basel), 2010, 2(4), 793-808.
[21]
Brahma, R.K.; McCleary, R.J.; Kini, R.M.; Doley, R. Venom gland transcriptomics for identifying, cataloging, and characterizing venom proteins in snakes. Toxicon, 2015, 93, 1-10.
[22]
Wang, Y.; Gao, H.; Shi, C.; Erhardt, P.W.; Pavlovsky, A. D, A.S.; Bledzka, K.; Ustinov, V.; Zhu, L.; Qin, J.; Munday, A.D.; Lopez, J.; Plow, E.; Simon, D.I. Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIbalpha. Nat. Commun., 2017, 8, 15559.
[23]
Coelho, A.L.; De Freitas, M.S.; Mariano-Oliveira, A.; Rapozo, D.C.; Pinto, L.F.; Niewiarowski, S.; Zingali, R.B.; Marcinkiewicz, C.; Barja-Fidalgo, C. RGD- and MLD-disintegrins, jarastatin and EC3, activate integrin-mediated signaling modulating the human neutrophils chemotaxis, apoptosis and IL-8 gene expression. Exp. Cell Res., 2004, 292(2), 371-384.
[24]
Moyle, M.; Foster, D.L.; McGrath, D.E.; Brown, S.M.; Laroche, Y.; De Meutter, J.; Stanssens, P.; Bogowitz, C.A.; Fried, V.A.; Ely, J.A. et al. A hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/CD18. J. Biol. Chem., 1994, 269(13), 10008-10015.
[25]
O’Bryant, Z.; Vann, K.T.; Xiong, Z.G. Translational strategies for neuroprotection in ischemic stroke--focusing on acid-sensing ion channel 1a. Transl. Stroke Res., 2014, 5(1), 59-68.
[26]
Chassagnon, I.R.; McCarthy, C.A.; Chin, Y.K.; Pineda, S.S.; Keramidas, A.; Mobli, M.; Pham, V.; De Silva, T.M.; Lynch, J.W.; Widdop, R.E.; Rash, L.D.; King, G.F. Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a. Proc. Natl. Acad. Sci. USA, 2017, 114(14), 3750-3755.
[27]
Sridharan, S.; Kini, R.M. Decoding the molecular switches of natriuretic peptides which differentiate its vascular and renal functions. Biochem. J., 2018, 475(2), 399-413.
[28]
Ferreira, S.H. A Bradykinin-potentiating factor (bpf) present in the venom of bothrops jararca. Br. J. Pharmacol. Chemother., 1965, 24, 163-169.
[29]
Ferreira, S.H.; Bartelt, D.C.; Greene, L.J. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry, 1970, 9(13), 2583-2593.
[30]
Gan, Z.R.; Gould, R.J.; Jacobs, J.W.; Friedman, P.A.; Polokoff, M.A. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J. Biol. Chem., 1988, 263(36), 19827-19832.
[31]
Egbertson, M.S.; Chang, C.T.; Duggan, M.E.; Gould, R.J.; Halczenko, W.; Hartman, G.D.; Laswell, W.L.; Lynch, J.J., Jr; Lynch, R.J.; Manno, P.D. et al., Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J. Med. Chem., 1994, 37(16), 2537-2551.
[32]
Scarborough, R.M.; Naughton, M.A.; Teng, W.; Rose, J.W.; Phillips, D.R.; Nannizzi, L.; Arfsten, A.; Campbell, A.M.; Charo, I.F. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J. Biol. Chem., 1993, 268(2), 1066-1073.
[33]
Scarborough, R.M.; Rose, J.W.; Hsu, M.A.; Phillips, D.R.; Fried, V.A.; Campbell, A.M.; Nannizzi, L.; Charo, I.F. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J. Biol. Chem., 1991, 266(15), 9359-9362.
[34]
Markwardt, F. The development of hirudin as an antithrombotic drug. Thromb. Res., 1994, 74(1), 1-23.
[35]
Maraganore, J.M.; Bourdon, P.; Jablonski, J.; Ramachandran, K.L.; Fenton, J.W., 2nd Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry, 1990, 29(30), 7095-7101.
[36]
Fox, I.; Dawson, A.; Loynds, P.; Eisner, J.; Findlen, K.; Levin, E.; Hanson, D.; Mant, T.; Wagner, J.; Maraganore, J. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb. Haemost., 1993, 69(2), 157-163.
[37]
Lisy, O.; Huntley, B.K.; McCormick, D.J.; Kurlansky, P.A.; Burnett, J.C., Jr Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J. Am. Coll. Cardiol., 2008, 52(1), 60-68.
[38]
Schweitz, H.; Vigne, P.; Moinier, D.; Frelin, C.; Lazdunski, M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem., 1992, 267(20), 13928-13932.
[39]
Cappello, M.; Vlasuk, G.P.; Bergum, P.W.; Huang, S.; Hotez, P.J. Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. Proc. Natl. Acad. Sci. USA, 1995, 92(13), 6152-6156.
[40]
Sherman, D.G.; Atkinson, R.P.; Chippendale, T.; Levin, K.A.; Ng, K.; Futrell, N.; Hsu, C.Y.; Levy, D.E. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA, 2000, 283(18), 2395-2403.
[41]
Kratzschmar, J.; Haendler, B.; Langer, G.; Boidol, W.; Bringmann, P.; Alagon, A.; Donner, P.; Schleuning, W.D. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene, 1991, 105(2), 229-237.
[42]
Gardell, S.J.; Duong, L.T.; Diehl, R.E.; York, J.D.; Hare, T.R.; Register, R.B.; Jacobs, J.W.; Dixon, R.A.; Friedman, P.A. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J. Biol. Chem., 1989, 264(30), 17947-17952.
[43]
Bajwa, S.S.; Kirakossian, H.; Reddy, K.N.; Markland, F.S. Thrombin-like and fibrinolytic enzymes in the venoms from the Gaboon viper (Bitis gabonica), eastern cottonmouth moccasin (Agkistrodon p. piscivorus) and southern copperhead (Agkistrodon c. contortrix) snakes. Toxicon, 1982, 20(2), 427-432.
[44]
Randolph, A.; Chamberlain, S.H.; Chu, H.L.; Retzios, A.D.; Markland, F.S., Jr; Masiarz, F.R. Amino acid sequence of fibrolase, a direct-acting fibrinolytic enzyme from Agkistrodon contortrix contortrix venom. Protein Sci., 1992, 1(5), 590-600.
[45]
Brinkhous, K.M.; Barnes, D.S.; Potter, J.Y.; Read, M.S. Von Willebrand syndrome induced by a Bothrops venom factor: bioassay for venom coagglutinin. Proc. Natl. Acad. Sci. USA, 1981, 78(5), 3230-3234.
[46]
Polgar, J.; Clemetson, J.M.; Kehrel, B.E.; Wiedemann, M.; Magnenat, E.M.; Wells, T.N.; Clemetson, K.J. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J. Biol. Chem., 1997, 272(21), 13576-13583.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
The Role of Chromenes in Drug Discovery and Development
New Avenues in Drug Discovery and Bioactive Natural Products
Practice and Re-Emergence of Herbal Medicine
Blood Oxidant Ties: The Evolving Concepts in Myocardial Injury and Cardiovascular Disease
Article Metrics
34
5
